A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies

PURPOSE: This was a phase I trial to determine the maximum tolerated dose and toxicity of deforolimus (AP23573, MK-8669), an inhibitor of mammalian target of rapamycin (mTOR). The pharmacokinetics, pharmacodynamics, and antineoplastic effects were also studied. EXPERIMENTAL DESIGN: Deforolimus was a...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Hartford, Christine M., Desai, Apurva A., Janisch, Linda, Karrison, Theodore, Rivera, Victor M., Berk, Lori, Loewy, John W., Kindler, Hedy, Stadler, Walter M., Knowles, Heather L., Bedrosian, Camille, Ratain, Mark J.
Format: Artigo
Jezik:Inglês
Izdano: 2009
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3147153/
https://ncbi.nlm.nih.gov/pubmed/19228743
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2076
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki